Egypt Pharmaceutical Market By Type (Pharmaceutical Drugs and Biologics), By Drug Classification (Branded Drugs and Generic Drugs), By Mode of Purchase (Prescription-Based Drugs and Over-the-counter Drugs), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Region, By Competition, Forecast & Opportunities, 2021-2031F

Market Overview

The Egypt Pharmaceutical Market size accounted for USD 1245.10 Million in 2025 and is predicted to increase from USD 1257.02 Million in 2026 to approximately USD 1823.95 Million by 2031, expanding at a CAGR of 6.57% from 2026 to 2031.

Key Takeaways

• By type, the pharmaceutical drugs segment accounted for the largest market share of approximately 88% in 2025, owing to their broad therapeutic applications, essential role in disease treatment, and consistent demand across hospitals, clinics, and pharmacies.
• By drug classification, the generic drugs segment held the largest market share of approximately 62% in 2025, supported by their cost-effectiveness, affordability, widespread availability, and strong adoption across major therapeutic categories.
• By mode of purchase, the prescription-based drugs segment emerged as the leading contributor in 2025, accounting for approximately 83% of the market, driven by the growing requirement for physician-supervised treatment and the widespread use of medicines for chronic and complex conditions.
• By distribution channel, retail pharmacies accounted for the largest market share of approximately 68% in 2025, supported by their extensive accessibility, proximity to consumers, recurring prescription refills, and ability to provide both prescription and non-prescription medicines.
• By region, Cairo accounted for the largest market share of approximately 35% in 2025, supported by its concentration of hospitals, specialist healthcare facilities, pharmacies, pharmaceutical distributors, medical professionals, and major commercial activities.
• Rising pharmaceutical consumption, increasing healthcare utilization, expansion of universal health coverage, growing chronic disease burden, pharmaceutical manufacturing localization, increasing adoption of specialized therapies, and expanding healthcare infrastructure are expected to drive the long-term growth of the Egypt Pharmaceutical Market.

Market Drivers

Large and Growing Population

Egypt’s large and expanding population provides a fundamental demand base for pharmaceutical products. According to the World Bank, Egypt’s population reached approximately 118.4 million in 2025, up from 116.5 million in 2024, representing annual population growth of around 1.6%. This expanding population increases the addressable base for prescription medicines, OTC products, vaccines, and treatments for acute and chronic diseases. Moreover, Egypt’s relatively young demographic profile is expected to sustain healthcare utilization over the long term, while population growth in both urban and rural areas should support broader pharmaceutical distribution and consumption. Consequently, demographic expansion is expected to remain a key structural driver of Egypt’s pharmaceutical market.

Rising Prevalence of Chronic Diseases

The growing burden of non-communicable diseases (NCDs) is a major driver of pharmaceutical demand in Egypt, particularly for cardiovascular, diabetes, oncology, and chronic respiratory therapies. WHO identifies NCDs as the country’s leading cause of death, accounting for an estimated 82% of total deaths.  Cardiovascular disease alone was associated with approximately 334,459 deaths in 2024, according to the World Heart Federation. Diabetes represents another substantial demand pool: the International Diabetes Federation estimates 13.2 million Egyptian adults were living with diabetes in 2024, equivalent to a 22.4% prevalence, with 62% of cases estimated to be undiagnosed. Rising diagnosis and long-term disease management should therefore sustain recurring pharmaceutical consumption.

Strengthening Pharmaceutical Regulation

Strengthening pharmaceutical regulation is supporting market growth by improving product quality, supply reliability, and investor confidence. The Egyptian Drug Authority (EDA), established under Law No. 151 of 2019, oversees the registration, circulation, quality control, and licensing of pharmaceutical products and manufacturing facilities. In December 2024, Egypt became the first African country to achieve WHO Maturity Level 3 for medicines regulation, following an assessment against more than 250 regulatory indicators; it had already achieved ML3 for vaccines in 2022. As of 2026, the EDA regulates a domestic manufacturing base of 177 medicine factories. In 2024, it conducted 115,000 inspections and issued 1,191 GMP certificates, strengthening compliance and facilitating pharmaceutical exports.

Download Free Sample Report

Market Restraints

Foreign Exchange Constraints and Import Dependence

Foreign-exchange constraints remain a significant structural restraint for Egypt’s pharmaceutical industry because domestic manufacturers continue to depend on imported active pharmaceutical ingredients (APIs), excipients, and other production inputs. The Egyptian Drug Authority (EDA) reported that shortages of hard currency during 2024 reduced imports of raw materials and contributed to the temporary unavailability of medicines. Although the EDA stated in February 2025 that 97–98% of previously reported medicine shortages had been resolved, the underlying exposure to foreign-currency availability remains relevant. The EDA is therefore prioritizing localization of API manufacturing; its 2026 strategy targets the localization of the 50 most-imported APIs, representing nearly 78% of human pharmaceutical API imports.

Informal and Unregulated Pharmaceutical Trade

Informal and unregulated pharmaceutical trade remains a restraint on Egypt’s pharmaceutical market by undermining the sales of licensed manufacturers and distributors while creating risks to product quality and patient safety. Despite strengthened regulatory enforcement, unauthorized medicines continue to circulate through unlicensed pharmacies, storage facilities, and online channels. In May 2026, the Egyptian Drug Authority (EDA) closed 85 unlicensed establishments across 17 governorates and seized pharmaceutical and related products valued at more than EGP 70 million. The EDA also identified 39 online pages and accounts involved in the illegal promotion and sale of medicines. Such activities can distort market pricing, weaken consumer confidence, and increase compliance and enforcement costs for legitimate pharmaceutical companies.

Stringent Pharmaceutical Price Controls

Egypt’s regulated pharmaceutical pricing system can constrain manufacturers’ margins, particularly when inflation, exchange-rate depreciation, and imported input costs rise rapidly. The Egyptian Drug Authority (EDA) uses a multi-stage pricing framework designed to balance medicine affordability with manufacturers’ financial sustainability, with prices reviewed in response to changes in production costs, inflation, and exchange rates. Following the 2024 exchange-rate liberalization, pharmaceutical companies sought price revisions to reflect higher production costs, prompting the EDA to reassess prices for selected medicines. The EDA reported that pricing decisions undergo nine stages before an increase is approved, potentially creating a time lag between cost escalation and price adjustments. This pressure can reduce profitability and discourage investment in lower-margin pharmaceutical products.

Market Opportunities

Expansion into African Pharmaceutical Markets

Egypt has a significant opportunity to expand its pharmaceutical presence across Africa by leveraging its established manufacturing base, regulatory capabilities, and geographic proximity to major African markets. Pharmaceutical exports reached approximately USD 1.3 billion in 2025, up from USD 1.07 billion in 2024, while exports to African countries increased from USD 299 million to USD 324 million during the same period. The EDA has set an ambitious target of increasing total pharmaceutical exports to USD 3 billion by 2030, including USD 1.34 billion directed toward African markets. The EDA’s WHO Maturity Level 3 status has also enabled regulatory reliance mechanisms in several African countries, potentially accelerating product registration and market access.

Development of High-Value and Complex Medicines

Egypt presents an emerging opportunity to develop high-value and complex pharmaceutical products, including biologics, oncology medicines, vaccines, and radiopharmaceuticals. The Egyptian Drug Authority (EDA) is actively supporting technology transfer and partnerships to expand domestic capabilities in these segments. In 2025, a USD 150 million GENNVAX facility was established to manufacture 29 vaccines and biological sera, targeting both Egyptian and African markets. The EDA has also initiated projects to localize oncology medicines and biological products through international technology-transfer partnerships. More recently, Poland’s Synektik proposed EUR 6–8 million in investment for local radiopharmaceutical tracer manufacturing. These developments create opportunities for companies with advanced technologies, manufacturing expertise, and specialized product portfolios.

Contract Manufacturing and Technology-Transfer Partnerships

Egypt offers an attractive opportunity for multinational pharmaceutical companies to establish contract manufacturing, licensing, and technology-transfer partnerships with local manufacturers. The Egyptian Drug Authority (EDA) is actively facilitating such collaborations to transfer advanced production technologies, strengthen local capabilities, and expand access to regional markets. In March 2026, the EDA and AstraZeneca discussed expanding product localization and investment in Egypt, with a focus on technology transfer and increasing manufacturing capabilities. Similarly, Abbott’s 2026 localization plans include advanced technology transfer, supply-chain development, and workforce capability building. These initiatives create opportunities for local manufacturers to access sophisticated technologies and for multinational companies to use Egypt as a production platform for domestic and regional markets.

Market Trends

Accelerating Digitalization of Pharmaceutical Regulation

Egypt’s pharmaceutical sector is undergoing a notable shift toward digital regulatory processes, with electronic submissions, integrated databases, and automated services increasingly becoming part of pharmaceutical registration and compliance. In June 2026, the Egyptian Drug Authority (EDA) launched Phase II of its Electronic Common Technical Document (eCTD) project, aimed at improving the efficiency and transparency of regulatory submissions. The EDA plans to operationalize its Regulatory Process Management system by February 2027, followed by full implementation of eCTD v4.0 in Q1 2028. The transition is also reflected in current service delivery, with the EDA completing more than 2,000 licensing procedures and issuing 9,405 electronic certificates and regulatory services during April–May 2026. This trend is reshaping how pharmaceutical companies manage registrations, documentation, approvals, and regulatory interactions.

Rising Focus on Rare-Disease Therapies

Egypt’s pharmaceutical market is increasingly witnessing a shift toward specialized therapies for rare diseases, supported by greater disease recognition, improved diagnosis, and stronger institutional attention to underserved patient populations. According to the Egyptian Drug Authority (EDA), pharmaceutical sales for rare diseases reached approximately EGP 15 billion in 2025, representing 3.6% of the total pharmaceutical market, while the segment recorded a 58% CAGR between 2020 and 2025. The government is also developing a National Strategy for Rare Diseases for 2026–2030, which includes establishing a national registry and integrating rare-disease data with the Egyptian Genome Project. These developments indicate a gradual transition toward more targeted treatment approaches and are likely to encourage greater availability of specialized medicines and diagnostic-linked therapies in Egypt.

Increasing Use of Smart Pharmaceutical Supply Chains

Egypt’s pharmaceutical industry is increasingly adopting digital and technology-enabled supply-chain practices to improve product visibility, inventory management, and distribution efficiency. The Egyptian Drug Authority (EDA) has been strengthening coordination among manufacturers, distributors, pharmacies, and healthcare institutions, while promoting digital tools for monitoring medicine movement across the supply chain. In 2026, Egypt had more than 183 pharmaceutical factories and over 1,000 production lines, increasing the need for sophisticated logistics and inventory-management systems. The introduction of pharmaceutical track-and-trace capabilities is further supporting the transition toward serialized and transparent distribution. These developments are encouraging pharmaceutical companies to adopt real-time inventory monitoring, digital documentation, product authentication, and data-driven logistics, making supply-chain digitalization an increasingly prominent feature of Egypt’s pharmaceutical market.

Market Report Coverage and Key Metrics

Market Segmentation Analysis

By Type Insights

Why Did Pharmaceutical Drugs Secure the Largest Share of the Egypt Pharmaceutical Market?

Pharmaceutical drugs are estimated to account for approximately 88% of Egypt’s pharmaceutical market, supported by their essential role in the treatment and management of a broad range of acute and chronic conditions. Prescription-based therapies generate recurring demand because patients often require continuous medication, particularly for long-term disease management. The segment also benefits from Egypt’s extensive network of hospitals, physicians, and pharmacies, which facilitates access to prescription medicines. In addition, pharmaceutical drugs encompass a broad product portfolio, including branded, generic, and specialized therapies, enabling manufacturers to address different patient and affordability requirements. Established prescribing practices and the clinical necessity of pharmaceutical treatments further reinforce their dominant position relative to OTC-oriented products.

By Drug Classification Insights

Why Did Generic Drugs Dominate the Egypt Pharmaceutical Market?

Generic drugs are estimated to account for approximately 62% of Egypt’s pharmaceutical market, supported primarily by their cost advantage and wider affordability compared with originator medicines. Lower development and production costs enable generic manufacturers to offer competitively priced therapies, making them particularly suitable for a price-sensitive patient population. Egypt’s established domestic manufacturing base also favors generic production, allowing local companies to supply a broad range of essential medicines. Government pricing and procurement policies further support generic utilization by encouraging cost containment and prioritizing affordable therapies. In addition, the availability of multiple generic alternatives across major therapeutic categories strengthens competition and improves patient access. The expiry of patents for established medicines also creates opportunities for generic substitution and broader market penetration.

By Mode of Purchase Insights

Why Did Prescription-Based Drugs Dominate the Egypt Pharmaceutical Market?

Prescription-based drugs are estimated to account for approximately 83% of Egypt’s pharmaceutical market, reflecting their essential role in treating conditions that require physician diagnosis, clinical supervision, and continued medication. Their dominance is supported by the greater complexity of therapies used for chronic and serious conditions, which typically require formal prescriptions and ongoing monitoring. Prescription medicines also benefit from their integration into hospital-based and physician-led treatment pathways, creating consistent demand across healthcare settings. In addition, prescription-based therapies encompass a broad range of therapeutic categories, including cardiovascular, metabolic, anti-infective, oncology, and other specialized treatments. The gradual formalization of healthcare delivery and greater emphasis on supervised treatment further reinforce the segment’s leading position over OTC medicines.

By Distribution Channel Insights

Why Did Retail Pharmacies Dominate the Egypt Pharmaceutical Market?

Retail pharmacies are estimated to account for approximately 68% of Egypt’s pharmaceutical market by distribution value. Their dominance is primarily supported by their high accessibility, proximity to patients, and ability to serve both prescription and non-prescription medicine needs. Retail pharmacies provide a convenient point of purchase for recurring medication requirements, particularly for chronic therapies that require regular refills. Their extensive geographic presence also enables pharmaceutical products to reach consumers beyond major hospitals and healthcare facilities. In addition, pharmacists play an important role in product selection, medication guidance, and substitution toward affordable alternatives, reinforcing the channel’s relevance. Compared with online pharmacies, retail outlets also provide immediate product availability and face-to-face interaction, supporting continued consumer preference for traditional pharmacy-based purchasing.

Download Free Sample Report

Market Regional Analysis: Cairo, Alexandria, Giza, Qalyubia, Port Said, Suez

Why Did Cairo Lead the Egypt Pharmaceutical Market?

Cairo is estimated to account for approximately 35% of Egypt’s pharmaceutical market, supported by its concentration of healthcare infrastructure, pharmaceutical companies, medical professionals, and distribution networks. As the country’s principal healthcare and commercial center, Cairo benefits from a dense network of hospitals, specialist clinics, pharmacies, and diagnostic facilities, generating strong demand for both routine and specialized medicines. The city also attracts patients from other governorates seeking advanced medical consultation and treatment, expanding its effective pharmaceutical demand base. In addition, the concentration of pharmaceutical manufacturers, distributors, wholesalers, and healthcare institutions facilitates efficient product availability and supply-chain coordination. The presence of leading medical institutions and specialist physicians further supports prescription generation, particularly for higher-value and specialized therapies.

Why Is Alexandria Expected to Register the Fastest Growth in the Egypt Pharmaceutical Market?

Alexandria is expected to register the fastest growth in Egypt’s pharmaceutical market due to its expanding healthcare infrastructure, strong medical ecosystem, and strategic position as a major commercial and logistics center. The city has a high concentration of hospitals, specialist facilities, pharmacies, and medical professionals, supporting increasing pharmaceutical consumption. Continued investment in university and specialized hospitals is expected to expand treatment capacity and encourage demand for prescription and specialized medicines. Alexandria’s established pharmaceutical manufacturing presence also strengthens local product availability and distribution capabilities. In addition, its major seaport and transportation connectivity facilitate the movement of pharmaceutical products and raw materials, supporting efficient regional distribution. These factors collectively provide a favorable environment for sustained pharmaceutical market expansion.

Key Market Players

• MDI Pharma
• Merck Ltd.
• Novartis Egypt
• Pharco Pharmaceuticals
• Roche Egypt
• Sanofi Egypt
• EVA Pharma
• Orchidia Pharmaceutical Industries
• GlaxoSmithKline Egypt
• Tabuk Pharmaceuticals Egypt

Recent Developments

In July 2026, the EDA announced approval of Egypt’s National Drug Policy, designed to strengthen pharmaceutical security and support progress toward WHO Maturity Level 4 in regulatory systems.

Egypt signed strategic partnerships in June 2026 to accelerate vaccine manufacturing and biotechnology technology transfer, strengthening domestic capabilities and regional health-security capacity.

In March 2026, Egypt launched the first phase of its national Pharmaceutical Track and Trace System, enabling medicines to be digitally monitored from manufacturing through distribution to patients.

Report Scope:

By Type

• Pharmaceutical Drugs
• Biologics

By Drug Classification

• Branded Drugs
• Generic Drugs

By Mode of Purchase

• Prescription-Based Drugs
• Over-the-counter Drugs

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Region

• Cairo
• Alexandria
• Giza
• Qalyubia
• Port Said
• Suez

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Egypt Pharmaceutical Market.

Available Customizations:

Egypt Pharmaceutical market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information